INNOVENT ANNOUNCES PHASE 2 CLINICAL STUDY OF PICANKIBART (IBI112) IN CHINESE PATIENTS WITH ULCERATIVE COLITIS MET PRIMARY ENDPOINT

Reuters · 10/17 00:00

Please log in to view news